Executive Summary
The 18 filings reveal a healthcare sector bifurcated between defensive capital allocators and pressured growth names. Cigna and Zoetis both reported mixed Q3 2026 results: Cigna grew revenue 5.6% YoY to $73.7B but net income fell 22.8% on prior-year gain comparisons, while Zoetis saw revenue decline 1.3% and net income drop 18.1%.
A striking cluster of insider selling emerged at IDEXX Laboratories, where four executives and directors sold shares worth over $13M in aggregate, and at Regeneron, where a director sold $6.7M. In contrast, passive institutional holders FMR and Regeneron's 13F show concentrated biotech bets. Capital allocation remains shareholder-friendly at Zoetis ($1.69B buyback) and Cigna ($3B modernization initiative), but margin pressures and macro headwinds in companion animal health and medical costs are evident. The filings suggest a sector navigating post-pandemic normalization, with insider activity skewing negative and guidance mixed.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Schedule 13G · 13F · 8-K · 10-Q · Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from November 04, 2026.
Investment Signals (12)
- Cigna Group ↓ (BULLISH)▲
Raised FY2026 adjusted EPS outlook to at least $30.60 and announced $3B 'Accelerate to One' modernization initiative, signaling confidence in long-term margin expansion despite Q3 net income decline
- Zoetis ↓ (BULLISH)▲
Adjusted diluted EPS rose 3% reported to $1.75 and FY2026 adjusted EPS guidance raised to $6.25-$6.35, while repurchasing $1.69B of stock in nine months, demonstrating commitment to shareholder returns
- Danaher ↓ (BULLISH)▲
FMR LLC (Fidelity) reported a 5.6% passive stake (39.2M shares) as of 9/30/2026, indicating continued institutional confidence in the life sciences tools leader
- Thermo Fisher Scientific ↓ (BULLISH)▲
FMR LLC disclosed a 6.0% passive stake (22.3M shares), reflecting steady institutional ownership in the diversified lab equipment provider
- Moderna ↓ (BULLISH)▲
FMR LLC increased its stake to 14.8% (58.9M shares), a significant vote of confidence in the mRNA platform despite sector volatility
- Regeneron Pharmaceuticals ↓ (BULLISH)▲
13F shows a concentrated $134.5M position in Parabilis Medicines (74.9% of portfolio), suggesting strategic bet on emerging biotech
- Cigna Group ↓ (BULLISH)▲
Q3 revenue grew 5.6% YoY to $73.7B, with nine-month revenue up 5.6%, indicating stable top-line momentum
- IDEXX Laboratories ↓ (BEARISH)▲
Multiple insiders sold shares at prices around $688-$706, potentially indicating they view the stock as fully valued near all-time highs
- Regeneron Pharmaceuticals ↓ (BEARISH)▲
Director Zoghbi sold 6,939 shares at $970.42 (~$6.73M) after exercising options at $380.95, a significant bearish signal from a board member
- Intuitive Surgical ↓ (BEARISH)▲
Two directors sold shares under 10b5-1 plans at ~$457-$460, totaling ~$5.1M, suggesting limited near-term upside perceived by insiders
- Zoetis ↓ (BEARISH)▲
U.S. Companion Animal revenue fell 8% on macro-driven price sensitivity and competition, a key drag on overall growth
- Cigna Group ↓ (BEARISH)▲
Q3 medical costs rose 8.4% YoY to $8,496M, outpacing revenue growth and pressuring margins
Risk Flags (9)
- IDEXX Laboratories↓ [HIGH RISK]▼
Four insiders (EVP Lane, Executive Chair Mazelsky, EVP Underberg, Director Junius) sold shares totaling over $13M in aggregate within a short window, a potential red flag on near-term prospects
- Regeneron Pharmaceuticals↓ [HIGH RISK]▼
Director Zoghbi's sale of $6.7M in stock (after option exercise) represents a significant bearish signal from a board member with deep company knowledge
- Zoetis↓ [HIGH RISK]▼
Q3 net income fell 18.1% YoY to $591M and diluted EPS dropped 12% to $1.44, with nine-month net income down 8.1%, indicating deteriorating profitability
- Cigna Group↓ [HIGH RISK]▼
Q3 shareholders' net income fell 22.8% YoY to $1,442M and diluted EPS declined 21.6% to $5.47, driven by absence of prior-year gain and higher medical costs
- Zoetis↓ [HIGH RISK]▼
U.S. Companion Animal revenue declined 8% due to macro-driven price sensitivity, dermatology competition, and generic competition, signaling persistent headwinds
- Cigna Group↓ [MEDIUM RISK]▼
Medical care ratio (MCR) rose to 85.0% from 84.8% YoY, and the company plans to exit the Individual and Family Plans medical business effective January 1, 2027, indicating challenges in that segment
- Intuitive Surgical↓ [MEDIUM RISK]▼
Two directors sold shares under 10b5-1 plans, totaling ~$5.1M, which may signal insiders see limited upside after strong stock performance
- Zoetis↓ [MEDIUM RISK]▼
Restructuring charges and acquisition/divestiture costs rose sharply to $142M for nine months from $34M, impacting profitability
- Cigna Group↓ [MEDIUM RISK]▼
Nine-month OCI loss of $1,666M pressured comprehensive income, reflecting investment portfolio headwinds
Opportunities (10)
- Cigna Group↓ (OPPORTUNITY)◆
Raised FY2026 adjusted EPS guidance to at least $30.60 and announced $3B modernization initiative, potentially driving margin expansion and operational efficiency
- Zoetis↓ (OPPORTUNITY)◆
Raised FY2026 adjusted EPS guidance to $6.25-$6.35 and continues aggressive share repurchases ($1.69B in nine months), supporting EPS growth despite revenue headwinds
- Moderna↓ (OPPORTUNITY)◆
FMR's increased stake to 14.8% suggests institutional confidence in the mRNA pipeline and potential upcoming catalysts
- Regeneron Pharmaceuticals↓ (OPPORTUNITY)◆
Concentrated 13F position in Parabilis Medicines ($134.5M) may indicate a strategic partnership or investment in a promising biotech, potentially leading to future collaboration
- Danaher↓ (OPPORTUNITY)◆
Fidelity's 5.6% passive stake and Thermo Fisher's 6.0% stake highlight institutional interest in life sciences tools, which may benefit from increased R&D spending
- IDEXX Laboratories↓ (OPPORTUNITY)◆
Despite insider selling, the stock trades near highs (~$700), reflecting strong fundamentals; any pullback could be a buying opportunity if growth reaccelerates
- Intuitive Surgical↓ (OPPORTUNITY)◆
Insider selling under 10b5-1 plans may be routine diversification; the company's dominant position in robotic surgery and recurring revenue model remain strong long-term
- Cigna Group↓ (OPPORTUNITY)◆
Exit from Individual and Family Plans business effective 2027 may improve margins by eliminating a underperforming segment
- Zoetis↓ (OPPORTUNITY)◆
International Companion Animal and Livestock segments showed strength, offsetting U.S. weakness; potential for recovery in U.S. as macro pressures ease
- Becton Dickinson↓ (OPPORTUNITY)◆
Q4 FY2026 results announced via 8-K; if results beat expectations, could be a positive catalyst (details in Exhibit 99.1)
Sector Themes (6)
- Insider Selling Cluster in Healthcare (BEARISH THEME)◆
7 insiders across IDEXX (4), Regeneron (1), and Intuitive Surgical (2) sold shares totaling over $18M in aggregate, suggesting widespread perception of full valuation or upcoming headwinds
- Mixed Q3 Results with Margin Pressure (MIXED THEME)◆
Cigna and Zoetis both reported revenue growth (5.6% and -1.3% respectively) but net income declines (22.8% and 18.1%), highlighting cost pressures and prior-year comparisons
- Shareholder-Friendly Capital Allocation (BULLISH THEME)◆
Zoetis repurchased $1.69B in nine months, Cigna announced $3B modernization, and both raised EPS guidance, indicating focus on shareholder returns despite challenges
- Institutional Concentration in Biotech (NEUTRAL THEME)◆
FMR holds significant stakes in Danaher (5.6%), Thermo Fisher (6.0%), and Moderna (14.8%), while Regeneron's 13F is concentrated in Parabilis Medicines, showing selective bets on life sciences and biotech
- Companion Animal Health Headwinds (BEARISH THEME)◆
Zoetis' U.S. Companion Animal revenue fell 8% on macro-driven price sensitivity and competition, a trend that may affect other animal health companies like IDEXX
- Medical Cost Trend Pressure (BEARISH THEME)◆
Cigna's medical costs rose 8.4% YoY, outpacing revenue growth, a concern for health insurers amid rising utilization
Watch List (8)
-
Q4 FY2026 results announced via 8-K; details in Exhibit 99.1 not yet analyzed, watch for earnings call and guidance for FY2027 [DATE: Nov 5, 2026]
-
Investor Day announced long-term targets and $3B modernization initiative; watch for further details on margin expansion and 2027 outlook [DATE: Nov 5, 2026]
- 👁
FY2026 guidance narrowed to $9.22-$9.32B revenue and raised EPS to $6.25-$6.35; watch for Q4 results and 2027 guidance [DATE: Early 2027]
- IDEXX Laboratories↓ (ONGOING)👁
Insider selling by four executives; monitor for further sales or potential 8-K announcements on business trends
- Regeneron Pharmaceuticals↓ (ONGOING)👁
Director Zoghbi's $6.7M sale; watch for additional insider activity or pipeline updates
- Moderna↓ (ONGOING)👁
FMR's increased stake to 14.8%; monitor for pipeline developments and regulatory milestones
-
Directors sold ~$5.1M under 10b5-1; watch for quarterly results and procedure growth trends [DATE: Q4 2026 earnings]
- Danaher and Thermo Fisher (ONGOING)👁
FMR passive stakes; monitor for any changes in institutional ownership or sector M&A activity
Filing Analyses
(18)
05-11-2026
FMR LLC (Fidelity), together with Abigail P. Johnson, reported beneficial ownership of 39,184,954.77 shares of Danaher Corp common stock as of September 30, 2026, representing 5.6% of the outstanding class under a Schedule 13G filed under Rule 13d-1(b). The filing is a routine passive-holder disclosure: FMR certifies the shares were acquired in the ordinary course and not to influence control, and the stake is spread across multiple Fidelity subsidiaries and advisers.
- · Filing is a LIVE Schedule 13G for the reporting date 09/30/2026, submitted November 5, 2026
- · FMR reports sole voting power over 35,309,085.54 shares and no shared voting power
- · Johnson family members control roughly 49% of FMR's voting power via Series B shares, and may be deemed a controlling group under the Investment Company Act of 1940
- · No other person is reported to have an interest in Danaher common stock exceeding 5% of the outstanding class
05-11-2026
CVS Health Corp filed its quarterly 13F-HR holdings report for the period ending September 30, 2026, disclosing 36 positions with an aggregate reported value of approximately $429.4 million. The portfolio is heavily concentrated in fixed-income and short-duration ETFs, led by iShares 1-5 Year Investment Grade ($169.0M), iShares Broad USD High Yield ($105.0M), and iShares 5-10 Year Investment Grade ($70.5M), alongside smaller equity exposures such as Vanguard S&P 500 ETF ($3.0M) and Select Sector SPDR Technology ($0.9M). The filing reflects a conservative, income-oriented allocation with minimal direct single-stock exposure, the largest being Prudential Financial at roughly $26.8M.
- · Portfolio is overwhelmingly fixed-income/short-duration focused, with the top three bond ETFs alone accounting for roughly $344.5M of the $429.4M total.
- · Equity exposure is minimal: Vanguard S&P 500 ETF at $3.0M, Select Sector SPDR Technology at $0.9M, and Invesco S&P 500 Equal Weight at $2.2M.
- · Direct single-stock holdings are limited, with Prudential Financial ($26.8M) the only notable individual equity position.
- · Other positions include SPDR Gold Shares ($2.0M), VanEck Gold Miners ($0.5M), and United States Brent Oil Fund ($6.0M).
- · Filing signed by Michael Motolo, Executive Director, dated November 5, 2026, for period ended September 30, 2026.
05-11-2026
FMR LLC (Fidelity), together with Abigail P. Johnson, filed a Schedule 13G reporting beneficial ownership of 22,261,362.05 shares of Thermo Fisher Scientific common stock as of September 30, 2026, representing 6.0% of the outstanding class. The filing is a passive ownership disclosure made under Rule 13d-1(b) and does not indicate any intent to influence control of the issuer.
- · Filing is a Schedule 13G under Rule 13d-1(b), indicating a passive institutional holder rather than an activist 13D filer
- · Sole voting power of approximately 20.2 million shares, with no shared voting power reported
- · Johnson family members control Series B voting shares of FMR LLC, representing 49% of its voting power, and may be deemed a controlling group under the Investment Company Act of 1940
- · Holdings are spread across multiple Fidelity subsidiaries and affiliates, with no other single person's interest exceeding 5% of the outstanding common stock
05-11-2026
The Cigna Group reported third quarter 2026 total revenues of $73.7 billion, up 6% from third quarter 2025, while shareholders' net income fell to $1.4 billion ($5.47 per share) from $1.9 billion ($6.98 per share), mainly due to the absence of a prior-year after-tax gain on sale. Adjusted income from operations was $2.1 billion ($7.98 per share), essentially flat versus $2.1 billion ($7.83 per share) a year earlier, as Pharmacy Benefit Services profit declined 22% while Cigna Healthcare and Specialty and Care Services grew. The company raised its full-year 2026 adjusted EPS outlook to at least $30.60 and announced long-term targets and a $3 billion 'Accelerate to One' modernization initiative at its 2026 Investor Day.
- · Specialty and Care Services adjusted revenues rose only about 1% YoY as lower specialty pharmacy revenue from biosimilar and generic adoption offset strong specialty distribution growth.
- · Cigna Healthcare MCR rose to 85.0% from 84.8% YoY, driven by U.S. Employer business mix, partially offset by lower MCR in Individual and Family Plans.
- · The company plans to exit the Individual and Family Plans medical business effective January 1, 2027.
- · Total behavioral customers fell 19% since year-end 2025 due to termination of a government contract, with minimal financial impact.
- · The 2026 Cigna Healthcare MCR outlook was narrowed by 50 bps to 84.2% +/- 25 bps.
- · Long-term targets include a 10%-14% adjusted EPS CAGR and roughly $50B in cumulative operating cash flow through 2030.
- · SG&A expense ratio rose to 4.9% from 4.8% YoY, reflecting investments in long-term growth partially offset by efficiencies.
05-11-2026
Becton, Dickinson and Company (BDX) issued a press release on November 5, 2026 announcing results for its fourth fiscal quarter ended September 30, 2026, furnished as Exhibit 99.1 under Item 2.02. The filing itself contains no quantitative results; the press release includes non-GAAP measures reconciled in schedules within that exhibit. Because the financial figures reside in Exhibit 99.1 rather than the 8-K body, the performance direction (positive, negative, or mixed) cannot be determined from this filing alone.
- · Fourth fiscal quarter results cover the period ended September 30, 2026
- · Press release includes non-GAAP measures with adjustments detailed in schedules to Exhibit 99.1
- · Outstanding debt securities listed on NYSE include 1.900% Notes due December 15, 2026, 1.213% Notes due February 12, 2036, 3.519% Notes due February 8, 2031, 3.828% Notes due June 7, 2032, and 3.855% Notes due May 20, 2033
05-11-2026
Zoetis reported Q3 2026 revenue of $2.4 billion, down 1% reported and organically, with GAAP net income of $591 million (down 18%) and diluted EPS of $1.44 (down 12%). Adjusted diluted EPS rose 3% reported to $1.75 (up 1% organic), while adjusted net income fell 5% reported and 7% organically. The company narrowed full-year 2026 revenue guidance to $9.220–$9.320 billion and raised adjusted EPS guidance to $6.25–$6.35, with Companion Animal pressure in the U.S. offset by Livestock and International strength.
- · U.S. Companion Animal revenue fell 8% on macro-driven price sensitivity, dermatology competition and generic competition
- · International Companion Animal revenue was flat organically, with lower sales of key dermatology products offsetting parasiticides and OA pain
- · Q3 pre-tax income fell 18% to $729 million; nine-month GAAP net income fell 8% to $1.883 billion
- · Q3 excluded items included $129M net impact from purchase accounting, acquisition/divestiture costs and significant items
- · Select 2027 product approvals now expected in Q4 2026; Convenia RTU for Dogs to be available to veterinarians in Q1 2027
- · Full-year guidance narrowed on revenue and adjusted EPS raised, but organic adjusted net income guidance is still a decline of 5-7%
05-11-2026
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 58,929,948.15 shares of Moderna, Inc. common stock as of September 30, 2026, representing 14.8% of the class, with sole dispositive power over 58,929,948.15 shares and sole voting power over 58,374,817.50 shares. The filing is a passive 13G made under Rule 13d-1(b) and includes a certification that the shares were not acquired to influence control of the issuer. Abigail P. Johnson is also reported as a beneficial owner through her control of FMR LLC.
- · Filing is a Schedule 13G/A (amendment) filed under Rule 13d-1(b) by an institutional investor, with reporting date as of 09/30/2026 and signed 11/04/2026
- · Filing reports no shared voting or dispositive power beyond what is listed; the Johnson family controls FMR LLC via Series B voting shares representing 49% of FMR LLC's voting power
- · Fidelity Management & Research Company LLC is the only subsidiary individually reported above 5% of Moderna's outstanding shares
05-11-2026
Zoetis reported Q3 2026 revenue of $2,391 million, down 1.3% from $2,422 million in Q3 2025, and nine-month revenue of $7,121 million, up 0.4% from $7,094 million. Net income attributable to Zoetis fell 18.1% YoY to $591 million in the quarter (diluted EPS $1.44 vs $1.63), and fell 8.1% to $1,883 million for nine months (diluted EPS $4.51 vs $4.60), while the company repurchased $1,690 million of treasury stock in the nine months and total debt was largely unchanged. Performance is mixed: top-line growth is flat to slightly negative, profitability declined, and capital returns were heavy.
- · Q3 2026 revenue declined 1.3% YoY while nine-month revenue was essentially flat (+0.4%), indicating top-line stagnation.
- · Q3 2026 other (income)/deductions swung to a $72 million expense from $12 million income in Q3 2025, a key driver of the profit decline.
- · Restructuring charges and certain acquisition/divestiture costs rose sharply to $142 million for nine months from $34 million.
- · Cash and cash equivalents fell 45.6% to $1,333 million from year-end 2025 as buybacks and dividends exceeded operating cash generation.
- · Net cash from operating activities declined 8.6% to $1,880 million for nine months.
- · Current portion of long-term debt is $750 million, up from zero at year-end 2025, creating near-term refinancing needs.
- · Shares outstanding fell to 407.5 million from 424.9 million at year-end 2025 through repurchases, supporting per-share metrics despite lower net income.
- · Q3 2025 figures were recast upward for revenue (+$22 million) and reduced for pre-tax income (-$1 million); nine-month 2025 net income was recast down $21 million to $2,049 million.
05-11-2026
Director GUTHART GARY S sold 10,000 Common Stock at $457.34 (~$4.57M). GUTHART GARY S holds 1,194,530 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director GUTHART GARY S sold 10,000 Common Stock at $457.34 (~$4.57M)
05-11-2026
Regeneron Pharmaceuticals filed its Q3 2026 13F-HR disclosing a $179.6M institutional holdings portfolio as of September 30, 2026, concentrated in three biotech equity positions. The largest holding is Parabilis Medicines at $134.5M (4,166,666 shares), followed by Intellia Therapeutics at $44.7M (3,702,995 shares) and Adicet Bio at just $60,511 (60,511 shares). All positions are sole-voting with no shared or discretionary allocation, indicating a highly concentrated, small-cap biotech-focused investment book rather than a diversified portfolio.
- · All three positions are held with sole voting authority; zero shares reported as shared or none voting
- · Portfolio is heavily concentrated: Parabilis Medicines alone accounts for ~74.9% of reported value
- · Adicet Bio position is immaterial at $60,511 (0.03% of portfolio)
- · Filing signed by Leonard Brooks, Senior Vice President, Treasurer, dated 11-05-2026 in Sleepy Hollow, NY
- · Report period is 09-30-2026; SEC file number 028-24826
05-11-2026
Co-Chief Scientific Officer MURPHY ANDREW J gifted 1,054 Common Stock. MURPHY ANDREW J holds 46,779 shares after the transaction.
- · Co-Chief Scientific Officer MURPHY ANDREW J gifted 1,054 Common Stock
05-11-2026
Director Zoghbi Huda Y sold 6,939 Common Stock at $970.42 (~$6.73M). 4 transactions reported in total. Zoghbi Huda Y holds 1,703 shares after the transaction.
- · Director Zoghbi Huda Y exercised/converted 7,439 Common Stock at $380.95 (~$2.83M)
- · Director Zoghbi Huda Y sold 6,939 Common Stock at $970.42 (~$6.73M)
- · Director Zoghbi Huda Y sold 500 Common Stock at $971.06 (~$486K)
- · Director Zoghbi Huda Y exercised/converted 7,439 Non-Qualified Stock Option (right to buy)
05-11-2026
Executive Vice President Lane Michael sold 2,059 Common Stock at $689.70 (~$1.42M). Lane Michael holds 4,076 shares after the transaction.
- · Executive Vice President Lane Michael sold 242.944 Common Stock at $687.85 (~$167K)
- · Executive Vice President Lane Michael sold 2,059 Common Stock at $689.70 (~$1.42M)
- · Executive Vice President Lane Michael sold 1,677 Common Stock at $687.46 (~$1.15M)
05-11-2026
Executive Chair of the Board MAZELSKY JONATHAN JAY exercised/converted 25,140 Common Stock at $178.26 (~$4.48M). 15 transactions reported in total. MAZELSKY JONATHAN JAY holds 83,803.302 shares after the transaction.
- · Executive Chair of the Board MAZELSKY JONATHAN JAY exercised/converted 25,140 Common Stock at $178.26 (~$4.48M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 1,945 Common Stock at $698.26 (~$1.36M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 4,075 Common Stock at $699.33 (~$2.85M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 1,667 Common Stock at $700.33 (~$1.17M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 4,540 Common Stock at $701.36 (~$3.18M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 2,136 Common Stock at $702.21 (~$1.5M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 3,950 Common Stock at $703.45 (~$2.78M)
- · Executive Chair of the Board MAZELSKY JONATHAN JAY sold 240 Common Stock at $705.59 (~$169K)
05-11-2026
EVP, GC & Corporate Secretary Underberg Sharon E. sold 6,348 Common Stock at $688.25 (~$4.37M). 5 transactions reported in total. Underberg Sharon E. holds 7,168.654 shares after the transaction.
- · EVP, GC & Corporate Secretary Underberg Sharon E. exercised/converted 8,906 Common Stock at $288.78 (~$2.57M)
- · EVP, GC & Corporate Secretary Underberg Sharon E. sold 6,348 Common Stock at $688.25 (~$4.37M)
- · EVP, GC & Corporate Secretary Underberg Sharon E. sold 1,503 Common Stock at $689.05 (~$1.04M)
- · EVP, GC & Corporate Secretary Underberg Sharon E. sold 1,055 Common Stock at $690.02 (~$728K)
- · EVP, GC & Corporate Secretary Underberg Sharon E. exercised/converted 8,906 Non-Qualified Stock Option (right-to-buy)
05-11-2026
Director JUNIUS DANIEL M sold 700 Common Stock at $705.78 (~$494K). JUNIUS DANIEL M holds 2,361 shares after the transaction.
- · Director JUNIUS DANIEL M sold 700 Common Stock at $705.78 (~$494K)
- · Director JUNIUS DANIEL M sold 500 Common Stock at $701.69 (~$351K)
05-11-2026
Director BARRATT CRAIG H sold 1,150 Common Stock at $460.00 (~$529K). BARRATT CRAIG H holds 1,150 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Director BARRATT CRAIG H exercised/converted 1,150 Common Stock at $90.49 (~$104K)
- · Director BARRATT CRAIG H sold 1,150 Common Stock at $460.00 (~$529K)
- · Director BARRATT CRAIG H exercised/converted 1,150 Non-Qualified Stock Option (right to buy)
05-11-2026
Cigna Group reported Q3 2026 total revenues of $73,683M, up 5.6% YoY from $69,748M, and nine-month revenues of $213,845M, up 5.6% from $202,428M. However, Q3 shareholders' net income fell 22.8% YoY to $1,442M (from $1,868M), diluted EPS declined 21.6% to $5.47 (from $6.98), and comprehensive income was pressured by a $1,666M nine-month OCI loss. Nine-month shareholders' net income rose modestly 0.7% to $4,756M.
- · Q3 2026 medical costs and other benefit expenses rose 8.4% YoY to $8,496M while nine-month medical costs fell 7.9% to $24,850M
- · Q3 2026 net investment gains were $36M versus $26M, and nine-month gains rose to $225M from $76M
- · Q3 2026 gain on sale of businesses was nil versus $38M a year earlier
- · Accumulated other comprehensive loss widened to $(4,472)M from $(2,806)M at December 31, 2025, driven by $(1,752)M nine-month long-duration insurance measurement adjustments
- · Short-term debt increased to $2,293M from $592M while long-term debt declined to $28,849M from $30,871M
- · Nine-month net cash used in investing activities narrowed to $(2,414)M from $(3,987)M; cash and cash equivalents fell to $6,186M from $7,676M
- · Nine-month operating cash flow declined 5.0% to $3,281M, weighed by a $2,964M outflow in pharmacy and other service costs payable
- · Accounts receivable rose to $31,492M from $28,768M at year-end, a $2,770M nine-month cash outflow
- · Q3 2026 net income attributable to noncontrolling interests rose to $256M from $105M, and nine-month to $678M from $291M
- · Nine-month share repurchases were $531M in cash flow, versus $2,620M in the prior-year period
Get daily alerts with 12 investment signals, 9 risk alerts, 10 opportunities and full AI analysis of all 18 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →November 05, 2026
US Pre-Market SEC Filings Roundup — November 05, 2026
US Pre-Market SEC Filings Roundup
November 05, 2026
US Executive Compensation Proxy SEC Filings — November 05, 2026
US Executive Compensation Proxy SEC Filings
November 05, 2026
US Earnings Financial Results SEC Filings — November 05, 2026
US Earnings Financial Results SEC Filings
November 05, 2026
US Merger & Acquisition SEC Filings — November 05, 2026
US Merger & Acquisition SEC Filings